Therapeutic targeting of CK2 in acute and chronic leukemias.

Francesca Buontempo, James A. McCubrey, E. Orsini, Maria Ruzzene, Alessandra Cappellini, Annalisa Lonetti, Camilla Evangelisti, Francesca Chiarini, C Evangelisti, J. T. Barata, Alberto Maria Martelli

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosis. High levels of CK2 mRNA and protein are associated with CK2 pathological functions in human cancers. Over the last decade, basic and translational studies have provided evidence of CK2 as a pivotal molecule driving the growth of different blood malignancies. CK2 overexpression has been demonstrated in nearly all the types of hematological cancers, including acute and chronic leukemias, where CK2 is a key regulator of signaling networks critical for cell proliferation, survival and drug-resistance. The findings that emerged from these studies suggest that CK2 could be a valuable therapeutic target in leukemias and supported the initiation of clinical trials using CK2 antagonists. In this review, we summarize the recent advances on the understanding of the signaling pathways involved in CK2 inhibition-mediated effects with a particular emphasis on the combinatorial use of CK2 inhibitors as novel therapeutic strategies for treating both acute and chronic leukemia patients
Original languageEnglish
JournalLeukemia
DOIs
Publication statusPublished - Sep 27 2017

Fingerprint

Leukemia
Protein Kinases
Neoplasms
Growth
Drug Resistance
Cell Survival
Therapeutics
Cell Proliferation
Clinical Trials
Apoptosis
Messenger RNA
Proteins

Cite this

Buontempo, F., McCubrey, J. A., Orsini, E., Ruzzene, M., Cappellini, A., Lonetti, A., ... Martelli, A. M. (2017). Therapeutic targeting of CK2 in acute and chronic leukemias. Leukemia. https://doi.org/10.1038/leu.2017.301

Therapeutic targeting of CK2 in acute and chronic leukemias. / Buontempo, Francesca; McCubrey, James A.; Orsini, E.; Ruzzene, Maria; Cappellini, Alessandra; Lonetti, Annalisa; Evangelisti, Camilla; Chiarini, Francesca; Evangelisti, C; Barata, J. T.; Martelli, Alberto Maria.

In: Leukemia, 27.09.2017.

Research output: Contribution to journalArticle

Buontempo, F, McCubrey, JA, Orsini, E, Ruzzene, M, Cappellini, A, Lonetti, A, Evangelisti, C, Chiarini, F, Evangelisti, C, Barata, JT & Martelli, AM 2017, 'Therapeutic targeting of CK2 in acute and chronic leukemias.', Leukemia. https://doi.org/10.1038/leu.2017.301
Buontempo F, McCubrey JA, Orsini E, Ruzzene M, Cappellini A, Lonetti A et al. Therapeutic targeting of CK2 in acute and chronic leukemias. Leukemia. 2017 Sep 27. https://doi.org/10.1038/leu.2017.301
Buontempo, Francesca ; McCubrey, James A. ; Orsini, E. ; Ruzzene, Maria ; Cappellini, Alessandra ; Lonetti, Annalisa ; Evangelisti, Camilla ; Chiarini, Francesca ; Evangelisti, C ; Barata, J. T. ; Martelli, Alberto Maria. / Therapeutic targeting of CK2 in acute and chronic leukemias. In: Leukemia. 2017.
@article{d1659fef84a54e1dab4a1360cb7e8dec,
title = "Therapeutic targeting of CK2 in acute and chronic leukemias.",
abstract = "CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosis. High levels of CK2 mRNA and protein are associated with CK2 pathological functions in human cancers. Over the last decade, basic and translational studies have provided evidence of CK2 as a pivotal molecule driving the growth of different blood malignancies. CK2 overexpression has been demonstrated in nearly all the types of hematological cancers, including acute and chronic leukemias, where CK2 is a key regulator of signaling networks critical for cell proliferation, survival and drug-resistance. The findings that emerged from these studies suggest that CK2 could be a valuable therapeutic target in leukemias and supported the initiation of clinical trials using CK2 antagonists. In this review, we summarize the recent advances on the understanding of the signaling pathways involved in CK2 inhibition-mediated effects with a particular emphasis on the combinatorial use of CK2 inhibitors as novel therapeutic strategies for treating both acute and chronic leukemia patients",
author = "Francesca Buontempo and McCubrey, {James A.} and E. Orsini and Maria Ruzzene and Alessandra Cappellini and Annalisa Lonetti and Camilla Evangelisti and Francesca Chiarini and C Evangelisti and Barata, {J. T.} and Martelli, {Alberto Maria}",
year = "2017",
month = "9",
day = "27",
doi = "10.1038/leu.2017.301",
language = "English",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Therapeutic targeting of CK2 in acute and chronic leukemias.

AU - Buontempo, Francesca

AU - McCubrey, James A.

AU - Orsini, E.

AU - Ruzzene, Maria

AU - Cappellini, Alessandra

AU - Lonetti, Annalisa

AU - Evangelisti, Camilla

AU - Chiarini, Francesca

AU - Evangelisti, C

AU - Barata, J. T.

AU - Martelli, Alberto Maria

PY - 2017/9/27

Y1 - 2017/9/27

N2 - CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosis. High levels of CK2 mRNA and protein are associated with CK2 pathological functions in human cancers. Over the last decade, basic and translational studies have provided evidence of CK2 as a pivotal molecule driving the growth of different blood malignancies. CK2 overexpression has been demonstrated in nearly all the types of hematological cancers, including acute and chronic leukemias, where CK2 is a key regulator of signaling networks critical for cell proliferation, survival and drug-resistance. The findings that emerged from these studies suggest that CK2 could be a valuable therapeutic target in leukemias and supported the initiation of clinical trials using CK2 antagonists. In this review, we summarize the recent advances on the understanding of the signaling pathways involved in CK2 inhibition-mediated effects with a particular emphasis on the combinatorial use of CK2 inhibitors as novel therapeutic strategies for treating both acute and chronic leukemia patients

AB - CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosis. High levels of CK2 mRNA and protein are associated with CK2 pathological functions in human cancers. Over the last decade, basic and translational studies have provided evidence of CK2 as a pivotal molecule driving the growth of different blood malignancies. CK2 overexpression has been demonstrated in nearly all the types of hematological cancers, including acute and chronic leukemias, where CK2 is a key regulator of signaling networks critical for cell proliferation, survival and drug-resistance. The findings that emerged from these studies suggest that CK2 could be a valuable therapeutic target in leukemias and supported the initiation of clinical trials using CK2 antagonists. In this review, we summarize the recent advances on the understanding of the signaling pathways involved in CK2 inhibition-mediated effects with a particular emphasis on the combinatorial use of CK2 inhibitors as novel therapeutic strategies for treating both acute and chronic leukemia patients

U2 - 10.1038/leu.2017.301

DO - 10.1038/leu.2017.301

M3 - Article

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -